亚盛医药-B:2025年中期报告

香港交易所
Sep 19, 2025

牛牛AI助理已提取核心讯息亚盛医药集团于2025年上半年实现收入人民币2.34亿元,其中耐立克®(奥雷巴替尼)在中国的销售收入同比增长93%至人民币2.17亿元。期内亏损为人民币5.91亿元,主要由于2024年同期确认一次性知识产权收入人民币6.78亿元所致。研发开支同比增加19%至人民币5.29亿元,主要用于推进全球临床试验。公司于2025年7月获中国国家药品监督管理局批准利生妥®(利沙托克拉)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10